GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | CDKN1A | decreases activity | EXP | | 6480464 | CTD | Sulindac results in decreased activity of CDKN1A protein | PMID:15190207 | CDKN1A | increases activity | EXP | | 6480464 | CTD | Sulindac results in increased activity of CDKN1A protein | PMID:14566837 | CDKN1A | increases expression | EXP | | 6480464 | CTD | Sulindac results in increased expression of CDKN1A mRNA; Sulindac results in increased expression of CDKN1A protein | PMID:11507085 PMID:17292881 PMID:18291362 PMID:18644992 | CDKN1A | multiple interactions | EXP | | 6480464 | CTD | [Sulindac co-treated with epigallocatechin gallate] results in increased expression of CDKN1A mRNA; CDKN1A protein promotes the reaction [Sulindac results in increased expression of and results in increased phosphorylation of MAPK8 protein]; CSK protein affects the reaction [Sulindac results in increased expression of CDKN1A protein]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of APP mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of CTSB mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of GBA1 mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of GRN mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of IL32 mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of ITGB3 mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of LGALS3 mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of LGALS3BP mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of SAA1 mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of SHC1 mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of SOD2 mRNA]; Sulindac inhibits the reaction [CDKN1A protein results in increased expression of TGM2 mRNA]; Sulindac promotes the reaction [CDKN1A protein results in decreased activity of CDK2 protein] | PMID:12628509 PMID:14566837 PMID:15190207 PMID:17292881 PMID:18644992 | CDKN1A | increases expression | ISO | Cdkn1a (Mus musculus) | 6480464 | CTD | Sulindac results in increased expression of CDKN1A mRNA; Sulindac results in increased expression of CDKN1A protein | PMID:15688007 PMID:16230399 PMID:17292881 | CDKN1A | increases response to substance | ISO | Cdkn1a (Mus musculus) | 6480464 | CTD | CDKN1A protein results in increased susceptibility to Sulindac | PMID:11507085 PMID:15688007 | CDKN1A | multiple interactions | ISO | Cdkn1a (Rattus norvegicus) | 6480464 | CTD | [Azoxymethane co-treated with Sulindac] results in increased expression of CDKN1A protein | PMID:18644992 | |
Go Back to source page | Continue to Ontology report |